Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema (DME)
August 12, 2024 07:45 ET
|
Eclipse Life Sciences
RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company focused on the development of novel therapies...
Age-Related Macular Degeneration (AMD) Market Forecast Report by Disease Type, Product, Distribution Channel, Countries, and Company Analysis: 2024-2032
August 08, 2024 06:55 ET
|
Research and Markets
Dublin, Aug. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032" report...
Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
June 24, 2024 09:27 ET
|
Spherix Global Insights
EXTON, PA., June 20, 2024, June 24, 2024 (GLOBE NEWSWIRE) -- The treatment landscape for Diabetic Macular Edema (DME) continues to evolve, with innovative therapies and emerging data significantly...
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
May 08, 2024 09:00 ET
|
Therini Bio, Inc.
THN391, a mAb designed to block neuroinflammation triggered by fibrin, demonstrated effectiveness in protecting against vascular and neuronal degeneration
Diabetic Retinopathy Market Surges to USD 13.23 Billion by 2030, Reflecting an 6.7% Growth | MarketDigits
February 09, 2024 04:00 ET
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to a research report "Diabetic Retinopathy Market”, By Type (Proliferative Diabetic Retinopathy, Diabetic Macular Edema (DME)), Treatment Type...
Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
November 01, 2023 14:55 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 01, 2023 (GLOBE NEWSWIRE) -- As U.S. ophthalmologists increasingly embrace a wider array of treatment options, the landscape of the diabetic macular edema (DME) market has...
Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak, Oxurion, Ocuphire, Bausch Health, KalVista, Allegro Opthalmics
October 04, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Macular Edema Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies to Watch Out - Novartis, Roche, Kodiak,...
Global Diabetic Retinopathy Market Size To Reach USD 103.2 BN By 2030 | CAGR 16.7%; Spherical Insights & Consulting
September 29, 2022 05:50 ET
|
SPHERICAL INSIGHTS LLP
New York, USA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Global Diabetic Retinopathy Market Size Was USD 3.8 Billion In 2020 And Is Projected To Reach USD 103.2 Billion By 2030, Grow A CAGR Of 16.7%....
Diabetic Macular Edema Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research & Programmes
May 12, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 12, 2021 (GLOBE NEWSWIRE) -- Diabetic Macular Edema Pipeline Sees Expansion Owing to Key Players, Key Therapies and Research & Programmes Diabetic Macular Edema...
AsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trials
February 23, 2021 08:00 ET
|
Notal Vision
Manassas, VA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Notal Vision, Inc. announced today that the company will provide AsclepiX Therapeutics with Home OCT monitoring services through its Notal Vision...